Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

17.00EUR
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
€17.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
272,740
52-wk High
€18.19
52-wk Low
€8.53

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.27
Market Cap(Mil.): €287.57
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Feb 2018

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

11 Dec 2017

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

05 Dec 2017

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment

07 Sep 2017

Earnings vs. Estimates